Company: RGNT
Filing Date: 2025-05-05
Form Type: F-1/A
Source: 0001213900-25-039589
Chunk: 98

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-05-05
Form: F-1/A
Chunk 98
---
 commissions and estimated offering expenses payable by us.

We currently expect to use
the net proceeds from this offering for the following purposes:

| ● | approximately $4.5 million for development activities (including the completion of our pivotal trial) and preparation of the PMA submission for GelrinC; |

| ● | approximately $1.0 million for operations (manufacturing, regulatory affairs and patents); |

| ● | approximately $0.5 million for research and development activities; |

| ● | approximately $0.5 million for EU marketing development (Medical Device Regulation qualification and scaleup); |

| ● | approximately $1.1                                                                                                       
 million for the repayment of the Bridge Loan, the loans under the 2024 Loan Agreements, the 2025 Loan Agreements and the 
 December 2024 Loan Agreement and accrued interest and applicable risk premium; and                                       |

| ● | the remainder for working capital and general corporate purposes and possible future acquisitions. |

Although we currently anticipate
that we will use the net proceeds from this offering as described above, there may be circumstances where a reallocation of funds is necessary.
Due to the uncertainties inherent in the clinical development and regulatory approval process, it is difficult to estimate with certainty
the exact amounts of the net proceeds from this offering that may be used for any of the above purposes on a stand-alone basis. Amounts
and timing of our actual expenditures will depend upon a number of factors, including our sales, marketing and commercialization efforts,
regulatory approval and demand for our product candidates, operating costs and other factors described under “Risk Factors”
in this prospectus. Accordingly, our management will have flexibility in applying the net proceeds from this offering. An investor will
not have the opportunity to evaluate the economic, financial or other information on which we base our decisions on how to use the proceeds
from this offering. For additional information regarding the repayment of the Bridge Loan, see “Certain Relationships and Related
Party Transactions – Other Financings.”

Based on our current plans,
we believe that our existing cash, cash equivalents and short-term deposits, will be sufficient to enable us to fund our operating expenses
and capital expenditure requirements through June 30, 2025. We anticipate that these funds, together with the net proceeds of this offering,
will be sufficient to fund our operating expenses and capital expenditure requirements through March 31, 2027, including the completion
of our pivotal trial for GelrinC with the two-year follow-up required by the FDA. We have based